Skip to main content
SpringerLink
Log in

Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Munro APS, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial The Lancet Infectious Diseases : 19 May 2022. Available from: URL: https://doi.org/10.1016/S1473-30992200271-7

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated. Reactions Weekly 1908, 7 (2022). https://doi.org/10.1007/s40278-022-15735-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-15735-7

Search

Navigation